These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35905459)

  • 21. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
    Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
    J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care.
    Pincus T; Yazici Y; Bergman MJ
    Rheum Dis Clin North Am; 2009 Nov; 35(4):773-8, viii. PubMed ID: 19962621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
    Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
    Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
    BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Disease Activity Score (DAS28) and Routine Assessment of Patient Index Data 3 (RAPID3) for Assessment of Rheumatoid Arthritis Disease Activity, in the Indian Setting.
    Shah A; Kini S; Londhey V
    J Assoc Physicians India; 2019 Jul; 67(7):58-60. PubMed ID: 31559770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
    Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
    Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.
    Mahmoud TG; Huang J; Frits M; Iannaccone C; Bykerk V; Bingham CO; Weinblatt M; Shadick NA
    J Rheumatol; 2020 Mar; 47(3):333-340. PubMed ID: 31203222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.
    Lie E; Woodworth TG; Christensen R; Kvien TK; Bykerk V; Furst DE; Bingham CO; Choy EH;
    Ann Rheum Dis; 2014 Oct; 73(10):1781-7. PubMed ID: 23852690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
    J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facilitators and barriers to adhere to monitoring disease activity with ePROs: a focus group study in patients with inflammatory arthritis.
    Seppen BF; Wiegel J; Nurmohamed MT; Bos WH; Ter Wee MM
    Rheumatol Int; 2023 Apr; 43(4):677-685. PubMed ID: 36627396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.
    Singh H; Gupta V; Ray S; Kumar H; Talapatra P; Kaur M; Kumar S; Arya S; Mathur R; Ghangas N
    Clin Rheumatol; 2012 Dec; 31(12):1663-9. PubMed ID: 22983768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation.
    Leung MH; Choy EHS; Lau CS
    Semin Arthritis Rheum; 2020 Aug; 50(4):749-758. PubMed ID: 32531504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care.
    Burgers LE; van der Pol JA; Huizinga TWJ; Allaart CF; van der Helm-van Mil AHM
    Arthritis Res Ther; 2019 May; 21(1):115. PubMed ID: 31064384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study.
    Saleem B; Brown AK; Quinn M; Karim Z; Hensor EM; Conaghan P; Peterfy C; Wakefield RJ; Emery P
    Ann Rheum Dis; 2012 Aug; 71(8):1316-21. PubMed ID: 22294638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
    Verstappen M; van Mulligen E; de Jong PHP; van der Helm-Van Mil AHM
    RMD Open; 2020 May; 6(1):. PubMed ID: 32393523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis.
    Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L
    Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.